Transition from low-grade endometrial stromal sarcoma to high-grade endometrial stromal sarcoma. 2010

Yoshiki Ohta, and Takao Suzuki, and Mutsuko Omatsu, and Shigeharu Hamatani, and Akira Shiokawa, and Miki Kushima, and Hidekazu Ota
Department of Pathology, Showa University, Northern Yokohama Hospital, Yokohama, Kanagawa, Japan. yomareko@cmed.showa-u.ac.jp

We report on a case of a primary low-grade endometrial stromal sarcoma (ESS) that progressed to a secondary high-grade ESS. In the secondary tumor, the immunohistochemical profile and focal tumor cell proliferation pattern suggested that this tumor was not truly undifferentiated, but possessed features of endometrial stroma. Low-grade ESS of our patient's primary tumor showed p53 protein overexpression, which is unusual in low-grade ESS, and her secondary high-grade ESS showed more prominent p53 immunoreactivity. This indicates that low-grade ESS that shows p53 immunoreactivity might progress to high-grade ESS, and it is considered that such cases of low-grade ESS should pay attention to the prognosis. Immunoreactivity for epidermal growth factor receptor was observed in both tumors, suggesting a relationship between the primary and secondary tumors in our case. Further study requires more immunohistochemical data for cases in which low-grade ESS transitions to high-grade ESS; in particular, data on epidermal growth factor receptor expression are necessary to define new therapeutic strategies for ESS.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D016159 Tumor Suppressor Protein p53 Nuclear phosphoprotein encoded by the p53 gene (GENES, P53) whose normal function is to control CELL PROLIFERATION and APOPTOSIS. A mutant or absent p53 protein has been found in LEUKEMIA; OSTEOSARCOMA; LUNG CANCER; and COLORECTAL CANCER. p53 Tumor Suppressor Protein,Cellular Tumor Antigen p53,Oncoprotein p53,TP53 Protein,TRP53 Protein,p53 Antigen,pp53 Phosphoprotein,Phosphoprotein, pp53
D016889 Endometrial Neoplasms Tumors or cancer of ENDOMETRIUM, the mucous lining of the UTERUS. These neoplasms can be benign or malignant. Their classification and grading are based on the various cell types and the percent of undifferentiated cells. Cancer of Endometrium,Endometrial Cancer,Endometrial Carcinoma,Cancer of the Endometrium,Carcinoma of Endometrium,Endometrium Cancer,Neoplasms, Endometrial,Cancer, Endometrial,Cancer, Endometrium,Cancers, Endometrial,Cancers, Endometrium,Carcinoma, Endometrial,Carcinomas, Endometrial,Endometrial Cancers,Endometrial Carcinomas,Endometrial Neoplasm,Endometrium Cancers,Endometrium Carcinoma,Endometrium Carcinomas,Neoplasm, Endometrial
D017809 Fatal Outcome Death resulting from the presence of a disease in an individual, as shown by a single case report or a limited number of patients. This should be differentiated from DEATH, the physiological cessation of life and from MORTALITY, an epidemiological or statistical concept. Fatal Outcomes,Outcome, Fatal,Outcomes, Fatal
D018203 Sarcoma, Endometrial Stromal A highly malignant subset of neoplasms arising from the endometrial stroma. Tumors in this group infiltrate the stroma with a wide range of atypia cells and numerous mitoses. They are capable of widespread metastases (NEOPLASM METASTASIS). Endometrial Stromal Sarcoma,Endometrial Stromal Sarcomas,Sarcomas, Endometrial Stromal,Stromal Sarcoma, Endometrial,Stromal Sarcomas, Endometrial
D066246 ErbB Receptors A family of structurally related cell-surface receptors that signal through an intrinsic PROTEIN-TYROSINE KINASE. The receptors are activated upon binding of specific ligands which include EPIDERMAL GROWTH FACTORS, and NEUREGULINS. EGF Receptor,Epidermal Growth Factor Receptor,Epidermal Growth Factor Receptor Family Protein,Epidermal Growth Factor Receptor Protein-Tyrosine Kinase,ErbB Receptor,HER Family Receptor,Receptor, EGF,Receptor, Epidermal Growth Factor,Receptor, TGF-alpha,Receptor, Transforming-Growth Factor alpha,Receptor, Urogastrone,Receptors, Epidermal Growth Factor-Urogastrone,TGF-alpha Receptor,Transforming Growth Factor alpha Receptor,Urogastrone Receptor,c-erbB-1 Protein,erbB-1 Proto-Oncogene Protein,EGF Receptors,Epidermal Growth Factor Receptor Family Proteins,Epidermal Growth Factor Receptor Kinase,HER Family Receptors,Proto-oncogene c-ErbB-1 Protein,Receptor Tyrosine-protein Kinase erbB-1,Receptor, ErbB-1,Receptors, Epidermal Growth Factor,Epidermal Growth Factor Receptor Protein Tyrosine Kinase,ErbB-1 Receptor,Family Receptor, HER,Family Receptors, HER,Proto oncogene c ErbB 1 Protein,Proto-Oncogene Protein, erbB-1,Receptor Tyrosine protein Kinase erbB 1,Receptor, ErbB,Receptor, ErbB 1,Receptor, HER Family,Receptor, TGF alpha,Receptor, Transforming Growth Factor alpha,Receptors, EGF,Receptors, Epidermal Growth Factor Urogastrone,Receptors, ErbB,Receptors, HER Family,c erbB 1 Protein,c-ErbB-1 Protein, Proto-oncogene,erbB 1 Proto Oncogene Protein

Related Publications

Yoshiki Ohta, and Takao Suzuki, and Mutsuko Omatsu, and Shigeharu Hamatani, and Akira Shiokawa, and Miki Kushima, and Hidekazu Ota
January 2013, European journal of gynaecological oncology,
Yoshiki Ohta, and Takao Suzuki, and Mutsuko Omatsu, and Shigeharu Hamatani, and Akira Shiokawa, and Miki Kushima, and Hidekazu Ota
December 2006, Gynecologic oncology,
Yoshiki Ohta, and Takao Suzuki, and Mutsuko Omatsu, and Shigeharu Hamatani, and Akira Shiokawa, and Miki Kushima, and Hidekazu Ota
March 1990, Gynecologic oncology,
Yoshiki Ohta, and Takao Suzuki, and Mutsuko Omatsu, and Shigeharu Hamatani, and Akira Shiokawa, and Miki Kushima, and Hidekazu Ota
January 2015, Pathology,
Yoshiki Ohta, and Takao Suzuki, and Mutsuko Omatsu, and Shigeharu Hamatani, and Akira Shiokawa, and Miki Kushima, and Hidekazu Ota
January 2018, Oncology research and treatment,
Yoshiki Ohta, and Takao Suzuki, and Mutsuko Omatsu, and Shigeharu Hamatani, and Akira Shiokawa, and Miki Kushima, and Hidekazu Ota
July 2003, Gynecologic oncology,
Yoshiki Ohta, and Takao Suzuki, and Mutsuko Omatsu, and Shigeharu Hamatani, and Akira Shiokawa, and Miki Kushima, and Hidekazu Ota
December 2007, International journal of colorectal disease,
Yoshiki Ohta, and Takao Suzuki, and Mutsuko Omatsu, and Shigeharu Hamatani, and Akira Shiokawa, and Miki Kushima, and Hidekazu Ota
September 2015, Diagnostic cytopathology,
Yoshiki Ohta, and Takao Suzuki, and Mutsuko Omatsu, and Shigeharu Hamatani, and Akira Shiokawa, and Miki Kushima, and Hidekazu Ota
August 2017, Gynecologic oncology,
Yoshiki Ohta, and Takao Suzuki, and Mutsuko Omatsu, and Shigeharu Hamatani, and Akira Shiokawa, and Miki Kushima, and Hidekazu Ota
March 2021, Genes, chromosomes & cancer,
Copied contents to your clipboard!